TME PHARMA CEO MESSAGE

GlobeNewswire Inc. | Sep 16, 2026 2:00 AM EDT

TME Pharma updates shareholders on final NOX-A12 license talks, capital discipline, minimal dilution, and capturing positive biotech market momentum.